Should HAS-BLED scoring be revised for better risk estimation in patients with intracerebral hemorrhage?. (August 2014)

• Record Type: Journal Article
• Authors: Ince, Birsen; Benbir, Gulcin; Gozubatik-Celik, Gokcen
• Is Part Of: Expert review of cardiovascular therapy. Volume 12:Number 8(2014)
• Page Start: 929
• Page End: 931
• Publication Date: 2014-08
• Subjects: Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/14779072.2014.931225
• Languages: English
• ISSNs: 1477-9072

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Many efforts have been made to develop decision-support tools and bleeding prediction schemes to start or resume anticoagulation after intracerebral hemorrhage, related with anticoagulation use or not, such as CHA₂DS₂-VASc or HAS-BLED scoring. HAS-BLED is a validated scoring system to predict the risk of major bleeding in a patient with atrial fibrillation; some current scientific guidelines suggest its use in 'risk–benefit' reasoning when deciding whether to start long-term oral anticoagulation. Here the authors present a patient with atrial fibrillation and intracerebral hemorrhage, and aim to discuss the use of HAS-BLED, suggesting that some revisions may help better management of these patients for major bleeding risk.</p> </abstract>